Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04293679 · ClinicalTrials.gov registry record · Phase 1
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC
A Phase 1 study of Bowen's Disease and Cutaneous Squamous Cell Carcinoma in Situ, sponsored by Sirnaomics.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT04293679 is a Phase 1 study of Bowen's Disease and Cutaneous Squamous Cell Carcinoma in Situ that has completed, run by Sirnaomics. The registered enrollment target is 25 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04293679, a Phase 1 study of Bowen's Disease and Cutaneous Squamous Cell Carcinoma in Situ, has completed, sponsored by Sirnaomics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label, dose escalation study to evaluate the safety and efficacy of intralesional injection of STP705 in adult patients with Cutaneous Squamous Cell Carcinoma in situ (isSCC, Bowen's disease). The purpose of this trial is to evaluate the safety, tolerability and efficacy of various doses of STP705 administered as Intralesional injection in subjects with isSCC. Goals: * To determine the safe and effective recommended dose of STP705 for the treatment of isSCC. * Analysis of biomarkers common to isSCC formation pathway including TGF-β1 and COX-2.
Conditions Studied
Interventions
- DRUG STP705
Study Locations (1)
Florida
- Center for Clinical and Cosmetic Research - Aventura
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2019-03-21 |
| Est. Completion | 2020-10-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04293679
The ClinicalTrials.gov registry entry for NCT04293679 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sirnaomics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Bowen's Disease appearing as the primary indexed condition, and to 1 intervention - of which STP705 is the first listed.
NCT04293679 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT04293679 about?
NCT04293679 is a clinical study titled "Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC". This is an open label, dose escalation study to evaluate the safety and efficacy of intralesional injection of STP705 in adult patients with Cutaneous Squamous Cell Carcinoma in situ (isSCC, Bowen's disease). The purpose of this trial is to evaluate the safety, tolerability and efficacy of various d...
What is the current status of trial NCT04293679?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2019-03-21. Estimated completion is 2020-10-21.
What conditions does trial NCT04293679 study?
This clinical trial studies the following conditions: Bowen's Disease, Cutaneous Squamous Cell Carcinoma in Situ.
What interventions are being tested in trial NCT04293679?
The interventions under investigation include: STP705 (DRUG).
Who is sponsoring clinical trial NCT04293679?
This trial is sponsored by Sirnaomics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04293679 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.